Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
The FDA granted Novavax’s COVID-19 vaccine Emergency Use Authorization after a lengthy and obstacle-riddled journey. It is authorized as a two-dose primary series for adults 18 years and older.
At the end of June, Novartis announced the latest data readouts in a long string of successes for tislelizumab. BioSpace spoke with Ken Kato, an investigator on the most recent RATIONALE 306 trial.
Kyowa Kirin announced it is dropping its Parkinson’s disease candidate, KW-6356, a follow-up to Nourianz, despite promising Phase II data that showed the drug is “potentially effective.”
The agreement with Merck brings $290 million upfront to Orion to access the latter’s investigational candidate, ODM-208, for mCPRC and other related drugs.
Aviv Clinics reported data from a study that suggests hyperbaric oxygen therapy may alleviate long COVID symptoms, particularly those associated with cognition.
Gossamer Bio sold shares of its common stock to pave its runway through mid-2024 while Teva and AbbVie reach deals in opioid settlements.
A multinational research collaboration has developed a new peptide dubbed “PATAS”, which appears to fix the metabolic abnormalities leading to type 2 diabetes (T2D).
Early data from Amgen’s ongoing trial on Lumakras for non-small cell lung cancer hinted at positive results from what could be a transformative combination of drugs versus cancer.
BioSpace takes a look at some of the recent legal battles and settlements related to the opioid epidemic across the industry.
Physicians at New York University have successfully implanted pig hearts into the bodies of patients that were living but no longer showed neural function, a process called xenotransplantation.
An NIH-sponsored trial assessing a combination of Humanigen’s lenzilumab and Gilead Sciences’ remdesivir in hospitalized COVID-19 patients failed to achieve the primary endpoint.
Sanofi, Certara, Pfizer and Thermo Fisher are facing hiring challenges head-on with a common strategy: upskilling programs. They use these programs to fill open roles while training and retaining existing talent.
